Status:
COMPLETED
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
Lead Sponsor:
Groupe Francais De Pneumo-Cancerologie
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Malignant Pleural Mesothelioma
Unresectable Malignant Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
Meso-Immune is a retrospective study to assess the efficacy and safety of the combination of Nivolumab and Ipilimumab used in first-line treatment of adult patients with unresectable Malignant Pleural...
Eligibility Criteria
Inclusion
- Patient with previously untreated and unresectable Malignant Pleural Mesothelioma treated with combination Nivolumab and Ipilimumab in the setting of the early access program
- Patient enrolled in the French National Health Insurance program or with a third-party payer
- Patient not opposed to the collection of his/her data (an information sheet will be to all living patients; for those who died, documented opposition to data collection in his/her medical file is not required)
Exclusion
- Patient under curatorship or guardianship
- Patient's explicit refusal to collect his / her data
- Patients not managed at the investigating center and not followed by a center investigator
Key Trial Info
Start Date :
May 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 27 2025
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT05308966
Start Date
May 3 2022
End Date
August 27 2025
Last Update
October 6 2025
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU du Pays d'Aix
Aix-en-Provence, France, 13616
2
CH Albi
Albi, France, 81013
3
CHU Angers
Angers, France, 49033
4
CH Argenteuil
Argenteuil, France, 95010